Canadian psychedelic company Numinus Wellness has entered a sales agreement with PharmAla Biotech, a Canadian biotechnology company. PharmAla will supply its GMP-certified LaNeo MDMA (3,4-methylenedioxymethamphetamine) for use in Numinus' upcoming clinical trial.
The clinical trial aims to investigate the feasibility of using a group model in MDMA-assisted psychotherapy, enrolling trainee practitioners as participants. This research seeks to determine the optimal number of therapists needed for safe program delivery and provide eligible trainees with practical experience in MDMA-assisted therapy. The trial application has been submitted to Health Canada for approval.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.